All In Biotech

Drug Trial Radar · NCT05695521

Regulatory T Cells for Amyotrophic Lateral Sclerosis

Phase 1 Safety Run-in Study and Phase 1b Randomized, Double Blinded, Placebo Controlled Trial

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Apr 3, 2023

Primary completion

May 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Cellenkos, Inc.Industry
Sponsor type
Industry
First posted
Jan 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells in additional 60 patients with Amyotrophic Lateral Sclerosis.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • CK0803Biological

    CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) will be administered intravenously

  • ExcipientOther

    Excipient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Limiting Toxicity (TLT)Time frame: 28 days
  2. Combined assessment of function and survival (CAFS)Time frame: 24 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Columbia University Irving Medical Center

    New York, New York

  • Baylor College of Medicine

    Houston, Texas

  • Michael E. DeBakey Veterans Affairs Medical Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.